Filing Flows › Ultralife (ULBI) › R&D spending
Ultralife (ULBI) R&D spending by quarter
Ultralife's R&D spending was $3.2M in Q3 2026 (third quarter 2026), -1% from Q2 2026. Over the last 7 quarters it ranged from $2.3M (Q2 2025) to $3.2M (Q2 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $3.2M | -1% | +12% |
| Q2 2026 | $3.2M | +9% | +39% |
| Q1 2026 | $3.0M | +5% | +23% |
| Q4 2025 | $2.8M | -1% | — |
| Q3 2025 | $2.9M | +23% | — |
| Q2 2025 | $2.3M | -4% | — |
| Q1 2025 | $2.4M | — | — |
Q3 2026 at a glance
Ultralife, Q3 2026: revenue $48.3M (+11% year over year), operating margin 6.6%, net earnings $2.4M, operating cash flow −$2.9M. The chart follows the revenue to costs, profit and cash.
Questions
What is Ultralife's R&D spending?
Ultralife's R&D spending was $3.2M in Q3 2026 (third quarter 2026), -1% from Q2 2026.
How has Ultralife's R&D spending changed?
Over the last 7 quarters it ranged from $2.3M (Q2 2025) to $3.2M (Q2 2026).